The lower levels of plasma sphingomyelins observed in APOE E2 in this study may be indicative of a protective effect of E2, as increased serum sphingomyelin species are associated with worse biomarkers and clinical measures of AD [89]. Here, APOE is linked to Alzheimer disease.